health π¬ Drug restores 100% hair growth in alopecia trial
A pill originally for arthritis showed major results in an alopecia areata trial. Up to 23% of patients in the Phase 3 UP-AA program in North America, Europe, and China achieved full regrowth. These findings, published on August 12, 2026, came from nearly 1,400 participants with severe hair loss. The drug, upadacitinib, blocks the JAK pathway, addressing this autoimmune condition. Researchers suggest longer treatment might bring even better outcomes for patients. π¬